Factor XI

Fewer than 26% of Chinese Patients with Atrial Fibrillation are Prescribed an Anticoagulant, while in Japan Almost One-Third of Patients are Undertreated Approximately 63% of Cancer…

<!-- Name:DistributionId Value:8832724 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third…

This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor…